Biological APIs Market to be Valued at US$ 122.97 Bn by 2031 | Growth Plus Reports

Newark, New Castle, USA, April 24, 2023 (GLOBE NEWSWIRE) — According to the latest Growth Plus Reports study, the global Biological APIs Market is projected to reach US$ 122.97 billion by 2031, with a revenue CAGR of 8.30%. The study examines major growth strategies, market dynamics and prospects, rivalry, changing market environment, market size, data and forecasts, and significant investment regions.

Key Takeaways:

• The increasing prevalence of chronic diseases will drive market revenue growth.
• Increasing demand for biological drugs will drive demand for biological APIs
• North America dominates the global biological APIs market. 

Get a Sample Copy of the Research Report: https://www.growthplusreports.com/inquiry/request-sample/biological-apis-market/8769

                                             Biological APIs Market Scope

Market Drivers
The increasng prevalence of chronic diseases such as cancer, diabetes, and cardiovascular diseases will drive the revenue growth of biological APIs market. Furthermore, increasing demand for biological drugs, increasing adoption of personalized medicine, and technological advancements are expected to boost the market revenue growth rate. 

Market Segmentation
Growth Plus Reports has analyzed global biological APIs market from four perspectives: Product Type, Therapy Area, Application, and Region.

Product Type Segmentation: Based on the product type, the global biological APIs market is segmented into proteins, antibodies, nucleic acids, and others. The antibodies segment dominates the market with the largest revenue share because antibodies are increasingly being used as therapies to treat a variety of ailments, including cancer, autoimmune disorders, and infectious diseases.

Therapy Area Segmentation: Based on the therapy area, the global biological APIs market is segmented into oncology, cardiovascular diseases, diabetes, autoimmune diseases, and others. The oncology segment dominates the market because biological products are often used to selectively target cancer cells.

Application Segmentation: Based on the application, the global biological APIs market is segmented into vaccines, interferon therapies, monoclonal antibody(mAb) therapies, insulin therapies, and growth hormones. The monoclonal antibodies (mAb) segment dominates the market because it is useful in the treatment of numerous disorders, including cancer, autoimmune diseases, and infectious diseases such as COVID-19.
  
Regional Growth Dynamics
Based on the region, the global biological APIs market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America dominates the global biological APIs market with the largest revenue share of the market. The increased frequency of chronic diseases such as cancer, diabetes, and cardiovascular disease, aging populations, unhealthy lifestyles, substantial funding for new biological API research and development, and modern healthcare infrastructure are the major factors responsible for North America’s significant revenue share in the global market.  

Request for Customization – https://www.growthplusreports.com/inquiry/customization/biological-apis-market/8769

Competitive Landscape

The prominent players operating in the global biological APIs market are:

• Pfizer Inc.
• Sanofi SA
• GlaxoSmithKline plc
• AbbVie Inc.
• Boehringer Ingelheim BioXcellence
• Fujifilm Diosynth Biotechnologies
• DSM Biologics
• Merck KGaA
• Celltrion Inc.
• Lonza Group AG
• Samsung BioLogics
• Teva Pharmaceutical Industries Ltd.

The biological APIs market is competitive with a number of global corporations. Leading players invest in technological advancements, research and development, and mergers and acquisitions to strengthen their market position.

Recent developments:

• Prevail Therapeutics, a biotechnology business focusing on researching gene treatments for neurological illnesses, was acquired by Eli Lilly and company in 2021. Lilly gained access to Prevail’s pipeline of gene treatments, including six in clinical development, as well as its patented gene therapy platform, as a result of the acquisition.
• Bristol Myers Squibb acquired Celgene Corporation in 2019, a biotechnology firm focused on developing biological APIs for cancer and other disorders. Bristol-Myers Squibb gained access to Celgene’s therapeutic pipeline, which included multiple blockbuster cancer medicines, as well as its manufacturing capabilities, as a result of the acquisition.

Table of Content

1. INTRODUCTION
   1. Market Ecosystem
   2. Timeline Under Consideration
      1. Historical Years – 2021
      2. Base Year – 2022
      3. Forecast Years – 2023 to 2031
   3. Currency Used in the Report
2. RESEARCH METHODOLOGY 
   1. Research Approach
   2. Data Collection Methodology
   3. Data Sources
      1. Secondary Sources 
      2. Primary Sources 
   4. Market Estimation Approach
      1. Bottom Up
      2. Top Down 
   5. Market Forecasting Model
   6. Limitations and Assumptions
3. PREMIUM INSIGHTS
   1. Current Market Trends (COVID-19 Perspective)
   2. Key Players & Competitive Positioning (2022)
   3. Regulatory Landscape
4. MARKET DYNAMICS
   1. Drivers
   2. Restraints/Challenges
   3. Opportunities
5. GLOBAL BIOLOGICAL APIS MARKET – ANALYSIS & FORECAST, BY PRODUCT TYPE
   1. Proteins
   2. Antibodies
   3. Nucleic Acids
   4. Others
6. GLOBAL BIOLOGICAL APIS MARKET – ANALYSIS & FORECAST, BY THERAPY AREA
   1. Oncology
   2. Cardiovascular Diseases
   3. Diabetes
   4. Autoimmune Diseases
   5. Others
7. GLOBAL BIOLOGICAL APIS MARKET – ANALYSIS & FORECAST, BY APPLICATION
   1. Vaccines
   2. Interferon Therapies
   3. Monoclonal Antibody(mAb) Therapies
   4. Insulin Therapies
   5. Growth Hormones

BIOLOGICAL APIS MARKET TOC

Buy this Premium Research Report:  https://www.growthplusreports.com/checkout-8769

VALUE PROPOSITIONS RELATED TO THE REPORT:

• Powered with Complimentary Analyst Hours and Expert Interviews with Each Report
• Comprehensive quantitative and qualitative insights at segment and sub-segment level
• Covid 19 impact trends and perspective
• Granular insights at global/regional/country level
• Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment
• Blanket coverage on competitive landscape
• Winning imperatives
• Exhaustive coverage on ‘Strategic Developments’ registered by leading players of the market

CUSTOMIZATION OPTIONS:

• Distributor Landscape Assessment
• Pricing Intelligence
• Customer Base Assessment
• Investment & Initiatives Analysis
• ‘Business Profile’ of Key Players

Schedule a call with our analyst: https://appoint.ly/s/salesZ3Jvd3RocGx1c3JlcG9ydHMuY29t/introduction

Visit our report store at – https://www.growthplusreports.com/report-store

Browse Latest Healthcare Related Reports:

Fibrous Dysplasia Market by Type (Monostotic Fibrous Dysplasia, Polyostotic Fibrous Dysplasia), Treatment (Surgery and Medication) – Global Outlook & Forecast 2023-2031

Stuttering Therapeutics Market by Type (Developmental Stuttering, Neurogenic Stuttering), Treatment (Cognitive Behavioral Therapy, Speech Therapy), End User (Hospitals, Specialty Clinics) – Global Outlook and Forecast 2023-2031

Catheter Introducer Sheaths Market by Product (Integrated Introducer Sheaths and Separable Introducer Sheaths), Application (Cardiology, Vascular), End User (Hospitals, Ambulatory Surgery Centers) – Global Outlook and Forecast 2023-2031

Medical Nitroglycerin Sprays Market by Application (Prophylaxis of Angina Pectoris, Acute Relief of Attack), Distribution Channel (Hospital Pharmacies, Retail Pharmacies) – Global Outlook and Forecast 2023-2031

Mastopexy Market by Technique (Benelli Lift, Crescent Breast Lift), End User (Specialty Clinics, Hospitals) – Global Outlook & Forecast 2023-2031

About Us:

Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).

Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.

We were awarded by the prestigious CEO Magazine as “Most Innovative Healthcare Market Research Company in 2020.